Do analysts prefer GLMD or CPIX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate GLMD or PLYX?

Polaryx Therapeutics has a consensus price target of $7.67, suggesting a potential upside of 285.26%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Polaryx Therapeutics is more favorable than Galmed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Polaryx Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Which has stronger valuation & earnings, GLMD or PLYX?

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galmed Pharmaceuticals N/A N/A -$10.31M -$7.28 N/A Polaryx Therapeutics N/A N/A -$8.98M -$0.08 N/A

Is GLMD or PLYX more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Galmed Pharmaceuticals N/A -35.32% -30.94% Polaryx Therapeutics N/A N/A N/A

Does the media prefer GLMD or PLYX?

In the previous week, Galmed Pharmaceuticals had 2 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 4 mentions for Galmed Pharmaceuticals and 2 mentions for Polaryx Therapeutics. Galmed Pharmaceuticals' average media sentiment score of 0.53 beat Polaryx Therapeutics' score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galmed Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Polaryx Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer GLMD or RFL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor GLMD or RFL?

In the previous week, Galmed Pharmaceuticals had 3 more articles in the media than Rafael. MarketBeat recorded 4 mentions for Galmed Pharmaceuticals and 1 mentions for Rafael. Rafael's average media sentiment score of 0.67 beat Galmed Pharmaceuticals' score of 0.53 indicating that Rafael is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galmed Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rafael 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, ALDX or GLMD?

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aldeyra Therapeutics N/A N/A -$33.85M -$0.39 N/A Galmed Pharmaceuticals N/A N/A -$10.31M -$7.28 N/A

Is ALDX or GLMD more profitable?

Galmed Pharmaceuticals' return on equity of -35.32% beat Aldeyra Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aldeyra Therapeutics N/A -53.14% -34.94% Galmed Pharmaceuticals N/A -35.32% -30.94%

Does the media prefer ALDX or GLMD?

In the previous week, Aldeyra Therapeutics had 6 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 10 mentions for Aldeyra Therapeutics and 4 mentions for Galmed Pharmaceuticals. Aldeyra Therapeutics' average media sentiment score of 0.83 beat Galmed Pharmaceuticals' score of 0.53 indicating that Aldeyra Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aldeyra Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Galmed Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate FBIO or GLMD?

Fortress Biotech presently has a consensus target price of $17.00, indicating a potential upside of 500.71%. Given Fortress Biotech's stronger consensus rating and higher probable upside, research analysts clearly believe Fortress Biotech is more favorable than Galmed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fortress Biotech 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to FBIO or GLMD?

In the previous week, Galmed Pharmaceuticals had 1 more articles in the media than Fortress Biotech. MarketBeat recorded 4 mentions for Galmed Pharmaceuticals and 3 mentions for Fortress Biotech. Galmed Pharmaceuticals' average media sentiment score of 0.53 beat Fortress Biotech's score of 0.34 indicating that Galmed Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortress Biotech 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Galmed Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Galmed Pharmaceuticals (GLMD) Competitors

$4.31 +0.26 (+6.42%)

Closing price 08/25/2026 03:59 PM Eastern

Extended Trading

$4.21 -0.10 (-2.23%)

As of 07:15 AM Eastern

Compare

GLMD vs. CPIX, PLYX, RFL, ALDX, and FBIO

Should you buy Galmed Pharmaceuticals stock or one of its competitors? Galmed Pharmaceuticals's main competitors and comparable companies include Cumberland Pharmaceuticals (CPIX), Polaryx Therapeutics (PLYX), Rafael (RFL), Aldeyra Therapeutics (ALDX), and Fortress Biotech (FBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Galmed Pharmaceuticals compare to Cumberland Pharmaceuticals?

Galmed Pharmaceuticals (NASDAQ:GLMD) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

Galmed Pharmaceuticals has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, Cumberland Pharmaceuticals has a beta of 0.08, indicating that its share price is 92% less volatile than the broader market.

76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. 19.8% of Galmed Pharmaceuticals shares are owned by company insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Galmed Pharmaceuticals has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -34.40%. Cumberland Pharmaceuticals' return on equity of -28.81% beat Galmed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galmed Pharmaceuticals	N/A	-35.32%	-30.94%
Cumberland Pharmaceuticals	-34.40%	-28.81%	-9.25%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Galmed Pharmaceuticals had 1 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 4 mentions for Galmed Pharmaceuticals and 3 mentions for Cumberland Pharmaceuticals. Cumberland Pharmaceuticals' average media sentiment score of 0.55 beat Galmed Pharmaceuticals' score of 0.53 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galmed Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cumberland Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cumberland Pharmaceuticals has higher revenue and earnings than Galmed Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$7.28	N/A
Cumberland Pharmaceuticals	$44.52M	2.93	-$2.84M	-$0.71	N/A

Summary

Cumberland Pharmaceuticals beats Galmed Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to Polaryx Therapeutics?

Galmed Pharmaceuticals (NASDAQ:GLMD) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Polaryx Therapeutics has a consensus price target of $7.67, suggesting a potential upside of 285.26%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Polaryx Therapeutics is more favorable than Galmed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, Galmed Pharmaceuticals had 2 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 4 mentions for Galmed Pharmaceuticals and 2 mentions for Polaryx Therapeutics. Galmed Pharmaceuticals' average media sentiment score of 0.53 beat Polaryx Therapeutics' score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galmed Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Polaryx Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Polaryx Therapeutics' return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galmed Pharmaceuticals	N/A	-35.32%	-30.94%
Polaryx Therapeutics	N/A	N/A	N/A

76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. 19.8% of Galmed Pharmaceuticals shares are owned by company insiders. Comparatively, 45.8% of Polaryx Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$7.28	N/A
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.08	N/A

Summary

Polaryx Therapeutics beats Galmed Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to Rafael?

Galmed Pharmaceuticals (NASDAQ:GLMD) and Rafael (NYSE:RFL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

In the previous week, Galmed Pharmaceuticals had 3 more articles in the media than Rafael. MarketBeat recorded 4 mentions for Galmed Pharmaceuticals and 1 mentions for Rafael. Rafael's average media sentiment score of 0.67 beat Galmed Pharmaceuticals' score of 0.53 indicating that Rafael is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galmed Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rafael	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.3% of Rafael shares are owned by institutional investors. 19.8% of Galmed Pharmaceuticals shares are owned by insiders. Comparatively, 32.9% of Rafael shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Galmed Pharmaceuticals has higher earnings, but lower revenue than Rafael. Rafael is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$7.28	N/A
Rafael	$920K	127.46	-$30.52M	-$0.68	N/A

Galmed Pharmaceuticals has a net margin of 0.00% compared to Rafael's net margin of -3,321.74%. Galmed Pharmaceuticals' return on equity of -35.32% beat Rafael's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galmed Pharmaceuticals	N/A	-35.32%	-30.94%
Rafael	-3,321.74%	-41.27%	-35.32%

Galmed Pharmaceuticals has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, Rafael has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Galmed Pharmaceuticals beats Rafael on 8 of the 12 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to Aldeyra Therapeutics?

Aldeyra Therapeutics (NASDAQ:ALDX) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Galmed Pharmaceuticals' return on equity of -35.32% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-53.14%	-34.94%
Galmed Pharmaceuticals	N/A	-35.32%	-30.94%

Aldeyra Therapeutics currently has a consensus price target of $5.50, indicating a potential upside of 254.84%. Given Aldeyra Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Aldeyra Therapeutics is more favorable than Galmed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.39	N/A
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$7.28	N/A

59.7% of Aldeyra Therapeutics shares are held by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 11.8% of Aldeyra Therapeutics shares are held by company insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Aldeyra Therapeutics has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market. Comparatively, Galmed Pharmaceuticals has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

In the previous week, Aldeyra Therapeutics had 6 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 10 mentions for Aldeyra Therapeutics and 4 mentions for Galmed Pharmaceuticals. Aldeyra Therapeutics' average media sentiment score of 0.83 beat Galmed Pharmaceuticals' score of 0.53 indicating that Aldeyra Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aldeyra Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Galmed Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Aldeyra Therapeutics beats Galmed Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to Fortress Biotech?

Fortress Biotech (NASDAQ:FBIO) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

Fortress Biotech has a net margin of 163.32% compared to Galmed Pharmaceuticals' net margin of 0.00%. Fortress Biotech's return on equity of 83.47% beat Galmed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	163.32%	83.47%	42.98%
Galmed Pharmaceuticals	N/A	-35.32%	-30.94%

Fortress Biotech presently has a consensus target price of $17.00, indicating a potential upside of 500.71%. Given Fortress Biotech's stronger consensus rating and higher probable upside, research analysts clearly believe Fortress Biotech is more favorable than Galmed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Fortress Biotech has higher revenue and earnings than Galmed Pharmaceuticals. Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$68.47M	1.38	$6.82M	$2.64	1.07
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$7.28	N/A

In the previous week, Galmed Pharmaceuticals had 1 more articles in the media than Fortress Biotech. MarketBeat recorded 4 mentions for Galmed Pharmaceuticals and 3 mentions for Fortress Biotech. Galmed Pharmaceuticals' average media sentiment score of 0.53 beat Fortress Biotech's score of 0.34 indicating that Galmed Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortress Biotech	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Galmed Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fortress Biotech has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market. Comparatively, Galmed Pharmaceuticals has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 28.5% of Fortress Biotech shares are held by insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Fortress Biotech beats Galmed Pharmaceuticals on 13 of the 15 factors compared between the two stocks.

Get Galmed Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GLMD vs. The Competition

Export

Metric	Galmed Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.22M	$12.52B	$7.34B	$12.72B
Dividend Yield	N/A	2.61%	2.53%	10.79%
P/E Ratio	-0.59	778.15	271.01	24.15
Price / Sales	N/A	758.07	627.95	102.20
Price / Cash	N/A	98.02	78.57	53.12
Price / Book	0.19	12.01	13.14	6.25
Net Income	-$10.31M	$2.80B	$3.46B	$347.86M
7 Day Performance	-9.64%	2.85%	1.51%	0.98%
1 Month Performance	5.04%	6.52%	8.81%	5.24%
1 Year Performance	-61.24%	8.04%	26.07%	17.04%

Galmed Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GLMD Galmed Pharmaceuticals	1.4215 of 5 stars	$4.31 +6.4%	N/A	-61.8%	$4.22M	N/A	N/A	20	Short Interest Decrease
CPIX Cumberland Pharmaceuticals	1.1111 of 5 stars	$7.76 +1.7%	N/A	+166.9%	$116.27M	$39.90M	N/A	80
PLYX Polaryx Therapeutics	3.5109 of 5 stars	$2.06 -1.4%	$7.67 +272.2%	N/A	$102.68M	N/A	N/A	11	News Coverage
RFL Rafael	0.4013 of 5 stars	$1.92 +3.2%	N/A	+51.7%	$99.84M	$920K	N/A	20	Gap Up
ALDX Aldeyra Therapeutics	3.7606 of 5 stars	$1.56 +0.3%	$5.50 +253.7%	-73.1%	$93.81M	N/A	N/A	10	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GLMD) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Galmed Pharmaceuticals (GLMD) Competitors

GLMD vs. CPIX, PLYX, RFL, ALDX, and FBIO

How does Galmed Pharmaceuticals compare to Cumberland Pharmaceuticals?

Summary

How does Galmed Pharmaceuticals compare to Polaryx Therapeutics?

Summary

How does Galmed Pharmaceuticals compare to Rafael?

Summary

How does Galmed Pharmaceuticals compare to Aldeyra Therapeutics?

Summary

How does Galmed Pharmaceuticals compare to Fortress Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLMD vs. The Competition

Galmed Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Galmed Pharmaceuticals (GLMD) Competitors

GLMD vs. CPIX, PLYX, RFL, ALDX, and FBIO

How does Galmed Pharmaceuticals compare to Cumberland Pharmaceuticals?

Which has more risk & volatility, GLMD or CPIX?

Do institutionals and insiders believe in GLMD or CPIX?

Is GLMD or CPIX more profitable?

Do analysts prefer GLMD or CPIX?

Does the media favor GLMD or CPIX?

Which has higher valuation and earnings, GLMD or CPIX?

Summary

How does Galmed Pharmaceuticals compare to Polaryx Therapeutics?

Do analysts rate GLMD or PLYX?

Does the media prefer GLMD or PLYX?

Is GLMD or PLYX more profitable?

Do institutionals & insiders hold more shares of GLMD or PLYX?

Which has stronger valuation & earnings, GLMD or PLYX?

Summary

How does Galmed Pharmaceuticals compare to Rafael?

Does the media favor GLMD or RFL?

Do institutionals and insiders have more ownership in GLMD or RFL?

Which has higher valuation & earnings, GLMD or RFL?

Is GLMD or RFL more profitable?

Which has more risk & volatility, GLMD or RFL?

Do analysts prefer GLMD or RFL?

Summary

How does Galmed Pharmaceuticals compare to Aldeyra Therapeutics?

Is ALDX or GLMD more profitable?

Do analysts prefer ALDX or GLMD?

Which has higher earnings and valuation, ALDX or GLMD?

Do insiders & institutionals believe in ALDX or GLMD?

Which has more volatility and risk, ALDX or GLMD?

Does the media prefer ALDX or GLMD?

Summary

How does Galmed Pharmaceuticals compare to Fortress Biotech?

Is FBIO or GLMD more profitable?

Do analysts rate FBIO or GLMD?

Which has preferable earnings and valuation, FBIO or GLMD?

Does the media refer more to FBIO or GLMD?

Which has more volatility & risk, FBIO or GLMD?

Do institutionals & insiders believe in FBIO or GLMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLMD vs. The Competition

Galmed Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools